High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel
Language English Country Netherlands Media print
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Biomarkers blood MeSH
- Diabetes Mellitus blood drug therapy MeSH
- Platelet Aggregation Inhibitors administration & dosage MeSH
- Interleukin-10 blood MeSH
- Clopidogrel MeSH
- Drug Resistance * MeSH
- Middle Aged MeSH
- Humans MeSH
- CD40 Ligand blood MeSH
- Leukocyte Count MeSH
- Aged MeSH
- Ticlopidine administration & dosage analogs & derivatives MeSH
- Age Factors MeSH
- Inflammation MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers MeSH
- IL10 protein, human MeSH Browser
- Platelet Aggregation Inhibitors MeSH
- Interleukin-10 MeSH
- Clopidogrel MeSH
- CD40 Ligand MeSH
- Ticlopidine MeSH
According to recent trials, a significant number of patients do not have a completely effective response to clopidogrel. The aim of the study was to evaluate the rate of clopidogrel resistance in the context of important clinical characteristics and to specifically determine the relation between clopidogrel efficacy and biomarkers of inflammation. Consecutive non-selected patients following PCI were enrolled into the study. All patients received a loading dose of 600 mg of clopidogrel. The effect of clopidogrel was assessed using the VerifyNow assay 24 h after clopidogrel administration, clopidogrel resistance was defined as PRU ≥ 240. At the same time, standard parameters of biochemistry and hematology, the concentration of anti-inflammatory cytokine interleukin-10 and of soluble CD40 ligand, were measured. 378 patients were enrolled. 243 (64.3%) patients were responders (R) and 135 patients (35.7%) were non-responders (NR). Non-responders were older (R 65.7 ± 13.3, NR 69.8 ± 11.5, P < 0.05), had a higher prevalence of diabetes (R 26.3%, NR 38.5%, P < 0.05), were more often on mechanical ventilation (R 0.8%, NR 4.4%, P < 0.05). The leukocyte count (R 9.8 ± 3.5, NR 11.7 ± 12.8, P < 0.05), and concentration of IL-10 (R 3.1 pg/ml, NR 5.7 pg/ml, P < 0.05) was higher among non-responders. The concentration of CD40L was not significantly different between the groups. In a multivariate logistic regression, older age, higher weight, female gender, mechanical ventilation, and a higher concentration of leukocytes and IL-10 were associated with an increased risk for being a non-responder. Older, obese patients, especially women had a higher risk of high on-treatment-platelet-reactivity. Higher concentrations of leukocytes and interleukin-10 were also an important factor associated with the risk of low clopidogrel responsiveness.
See more in PubMed
Clin Cardiol. 2009 Oct;32(10):561-8 PubMed
Am Heart J. 2008 May;155(5):806-16 PubMed
Platelets. 2001 Mar;12(2):74-82 PubMed
Clin Sci (Lond). 2009 Apr;116(8):651-8 PubMed
Circulation. 2003 Apr 29;107(16):2109-14 PubMed
Circulation. 2009 Jan 20;119(2):237-42 PubMed
Catheter Cardiovasc Interv. 2010 Feb 1;75(2):158-66 PubMed
J Cardiovasc Pharmacol. 2009 May;53(5):368-72 PubMed
Heart. 2011 Oct;97(20):1661-7 PubMed
Circ J. 2007 Jul;71(7):1086-91 PubMed
JAMA. 2002 Nov 20;288(19):2411-20 PubMed
Circulation. 2003 Sep 2;108(9):1049-52 PubMed
Angiology. 2012 Jan;63(1):62-6 PubMed
J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33 PubMed
JAMA. 2011 Mar 16;305(11):1097-105 PubMed
J Am Coll Cardiol. 2002 Nov 20;40(10):1761-8 PubMed
Eur Heart J. 2008 Apr;29(8):992-1000 PubMed
N Engl J Med. 2005 Mar 24;352(12):1179-89 PubMed
Circ Cardiovasc Interv. 2010 Jun 1;3(3):277-83; discussion 283 PubMed
JAMA. 2010 Feb 24;303(8):754-62 PubMed
JAMA. 2009 Aug 26;302(8):849-57 PubMed
